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Erythrocytes  infected  with  Plasmodium  schizonts,  as  well  as  the  merozoites 
released by these cells, bear surface proteins of Mr 195,000-250,000, depending 
on the parasite species (1-9). These proteins and their degradation products (1, 
7,  10,  11)  are  immunogenic  during  natural  malarial  infections,  and  there  is 
evidence that antibodies against these antigens interfere with parasite  multipli- 
cation during erythrocytic schizogony, both in vivo and in vitro (12-14).  Anti- 
bodies against the P. falciparum  (pf)l Mr  195,000 and the P.  chabaudi (Pch) Mr 
250,000 components correlate positively with in vivo protection of human and 
murine hosts, respectively (4, 6). Murine mAb against the Mr 230,000 protein of 
P.  yoelii  (Py) that  can  confer passive protection  in  mice (2),  and  murine  mAb 
against the Mr 230,000 component ofP. knowlesi (Pk) inhibit the in vitro growth 
of this parasite by interference with merozoite invasion (15). The concentrations 
of  mouse  mAb  required  to  inhibit  the  growth  of  primate  Plasmodium  are 
unphysiologically high,  >0.1  mg/ml,  relative to the expected antibody concen- 
trations  in  sera of the protected hosts (15).  However, human  IgG from  EBV- 
transformed  human  B  iymphocytes of Gambian  adults  immune  to  Pf malaria 
contain antibody to the Pf Mr  195,000 component that inhibit  in vitro parasite 
growth at concentrations <100 ng/ml  (16).  The  most direct evidence that  this 
category of high-Mr Plasmodium  components may induce a  protective immune 
response  in  vivo  is  derived  from  vaccination  trials  in  three  compatible  host- 
parasite systems. Repeated injection of Pf Mr  195,000 and Py Mr 230,000 with 
CFA  into  aotus  monkeys and  BALB/c  mice,  respectively,  yielded partial  but 
effective  protection  against  potentially  lethal  parasite  challenges  (10,  17).  A 
similar  protection  of rhesus  monkeys across  different  Pk  strains  was  induced 
using a  Pk Mr 74,000 glycoprotein derived from the Pk Mr 230,000 component 
(7).  The  close  correlation  between  antibody-mediated  growth  inhibition  and 
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protective immunity make human mAb an ideal reagent to examine the mecha- 
nism of protection against Pf in man. 
For  this  reason,  we  have  used  recent  advances  in  the  production  of human 
mAb by the  hydridoma  technique  (18-24)  and  fused  PBL  of Gambian adults 
immune  to  Pf malaria  with  GM4672  cells,  a  human  lymphoblastoid  cell  line 
(LCL) (20, 21). Hybridoma-derived mAb were screened for immune fluorescence 
reaction with Pf schizonts, for in vitro parasite growth inhibition, and for immune 
precipitation reaction with the PfMr  195,000  protein. 
Materials and  Methods 
Reagents.  Reagents  of highest  purity  available  were  obtained  from  the  following 
suppliers: PEG (of 1,500 mol wt), fromJ. T. Baker Chemical Co. (Phillipsburg, NJ); PWM, 
nonessential amino acids, L-glutamine, and sodium pyruvate from Gibco (Grand Island, 
NY); FBS,  (lot  110463)  from HyClone Laboratories (Logan, UT); NCTC  109 medium 
from Whittaker M. A. Bioproducts (Walkersville, MD); Ficoll-Paque from Pharmacia Fine 
Chemicals (Piscataway, N  J); hypoxanthine (H), thymidine (T), aminopterin (A),  glycine, 
Hepes, 6-mercaptopurine, oxaloacetic acid, bovine insulin, alkaline phosphatase-deriva- 
tized goat IgG against human  IgG and IgM, and paranitrophenyl phosphate tablets, all 
from Sigma Chemical Co. (St.  Louis, MO); chromatographically purified human IgG and 
IgM, goat IgG against human  IgG and  IgM from Cooper Biochemical, Inc. (Malvern, 
PA);  mAb specific for human  IgG subclasses and light chains from Bethesda Research 
Laboratories,  Inc.  (Gaithersburg,  MD);  [35S]methionine  from  New  England  Nuclear 
(Boston, MA). 
Media.  The medium used for PWM-stimulation of PBL and for maintenance of the 
human LCL was RPMI  1640 (Gibco) containing 0.01  Hepes, 0.001  M sodium pyruvate, 
0.004 M L-glutamine, four times the concentration of nonessential amino acids, and 11.5% 
FBS; this medium is referred to as RPMI/Hepes (21).  The hybridoma selection medium 
is RPMI/Hepes medium containing  10%  (vol/vol) NCTC  109 medium, 0.003  M oxalo- 
acetic acid 0.0025 IU/ml insulin, 3.6 x  10 -4 M H, 3.9 X 10 -5 M T, and 3.5 x  10  -7 M A. 
Cells.  GM  4672  cells  containing  a  small  number  of EBV  DNA  copies  (based  on 
hybridization with EBV DNA [David Thorley-Lawson, personal communication]; the cells 
had previously tested negative for EBV nuclear antigen) were used as fusion partner (18, 
21).  For one week every month and one week before fusion, the cells were grown  in 
RPMI/Hepes containing 10 -4 M 6-mercaptopurine. 
PBL from three Gambian adults (K. D., K. J., and S. R.), solidly immune of Pf malaria, 
were isolated from freshly drawn heparinized blood. 4 ml of blood was layered atop 3 ml 
of Ficoll-Paque and centrifuged at 104 g. After removal of plasma and platelets, the PBL 
were washed twice in RPMI/Hepes and then cultured in this medium containing PWM 
(1:1,000 dilution) at a cell density of 106 cells/ml, at 37°C and 5% C02/95% air for 5-7 
d. 
Fusion.  Before fusion, I07 cells of each PWM-stimulated PBL and GM4672 cells were 
washed  twice  in  serum-free  RPMI/Hepes  and  pelleted  together.  The  cell  pellet  was 
overlaid with 0.5 ml of 44% PEG (21),  suspended, and pelleted at 300 g for 3 rain. The 
PEG was diluted by dropwise addition of 10 ml of serum-free RPMI/Hepes over a period 
of 5  min, and the cells were pelleted again at 500 g  for 5  min.  The supernatant fluid 
containing PEG was removed, the cells suspended in RPMI/Hepes maintained at 37°C, 
5% CO~/95%  air for 24 h,  washed, suspended in  RPMI/Hepes/HAT, and plated into 
microtiter plates at a  cell density of 2  X  l0 p cells/well (19).  The cells were refed twice 
weekly, and monitored for growth of colonies once a week. 
Cloning.  Proliferating cells  producing antiplasmodial  Ig (see  below),  were  first  ex- 
panded  into  several  macrotiter  wells  and  then  cloned  twice  by  limiting  dilution  into 
microtiter flat-bottom plates at densities of 30 and 0.3 cells/well. The cells were screened 
and refed once a week. 
Plasmodium Culture.  The Gambian K 1 isolate of Pf was maintained in O  Rh + eryth- SCHMIDT-ULLRICH  ET  AL.  181 
rocytes and serum as in Trager and Jensen (25), and synchronized weekly using gelatin 
(26).  Metabolic  labeling  employed RPMI  containing  20%  of the  normal  methionine 
concentration plus [35S]methionine at a concentration of 0.1  mCi/ml. 
Screening for Antiplasmodial Antibodies.  The antibody concentration of supernatants 
was screened using an ELISA, in polystyrene 96-well microtiter plates (Dynatech Labo- 
ratories, Inc.; Alexandria, VA).  The plates were coated with human  IgG or IgM,  2.0 
~g/ml each, solubilized in 0.05 M sodium borate, pH 8.5. The equilibration with culture 
supernatants and development with alkaline phosphatase-derivatized antibodies and p- 
nitrophenyl phosphate as substrate was as in Schoenfeld et al. (21). The same ELISA was 
used to determine the Ig isotype and IgG subclass of mAb. 
Antiplasmodial antibodies in culture supernatants that tested positive by ELISA were 
identified using indirect immune fluorescence. Acetone-fixed blood films of Pf cultures 
(1% hematocrit) at ~10% parasitemia were preincubated with goat serum at a dilution of 
1:50, washed, incubated with the hybridoma supernatants for 30 min at 37°C, and washed 
again.  Fluorescein-labeled goat IgG against human  IgG and IgM was incubated for 30 
min at 37°C. After extensive washing in PBS, the slides were counterstained with Evans 
Blue and evaluated using a Zeiss epifluorescence microscope. 
Supernatants of cloned hybridomas were used to assess the in vitro growth inhibition 
of Pf by the antiplasmodial antibodies. Gelatin-synchronized Pf  cultures (26) were initiated 
at a parasitemia of-<1% and carried for 72 h in RPMI  1640 medium, refeeding daily as 
in Trager andJensen (25). Each supernatant/serum was tested in triplicate. The metabolic 
labeling was done between 36 and 72 h of the culture, using RPMI 1640 containing 20% 
of the normal methionine concentration and 0.1  mCi/ml [sSS]methionine.  The degree of 
inhibition was expressed relative to parasite growth obtained with hybridoma supernatants 
not producing antiplasmodial antibodies and Ig isolated from the sera of the immune PBL 
donors and of nonimmune individuals (27). 
Immunochemical Techniques.  To test for monoclonality of antibodies secreted by hy- 
bridomas, we selected only supernatants that, by ELISA, tested positive 10-fold above the 
background of the GM4672 cells.  To metabolically label the IgG/IgM, the hybridomas 
were incubated during exponential growth in presence of [sSS]methionine,  0.05 mCi/ml, 
in methionine-free RPMI/Hepes. The Ig was purified on affinity columns using Sepharose 
4 B-immobilized goat anti-human Ig. Specifically bound human Ig was eluted with 0.2 
M glycine, pH 2.4. The Ig was dialysed against 0.15 M NaCI, concentrated, and subjected 
to bidimensionai  IEF and SDS-PAGE (28).  Heavy and light chains were identified by 
autoradiography. 
[35S]methionine-labeled Pf antigens  reacting  with  human  mAb  were  identified  by 
immune precipitation as previously described (7). Preabsorption of  the antigen, the specific 
immune deposition with mAb, and fractionation of precipitated Pf antigens by SDS-PAGE 
was also as previously described (7). 
Results 
Donor Lymphocytes.  30 ml of blood from each of the Gambian adults S. R., K. 
J., and K. D. yielded 2  x  107, 3.5 x  107, and 4  x  10 7 PBL, respectively. After 7 
d  of  PWM-stimulation,  we  recovered  60-80%  of  the  PBL  for  fusion  with 
GM4672  cells.  The  majority  of PBL  formed  large  clumps  of blast  cells  with 
pseudopod extrusions  typical for B  lymphocytes. The  PBL were relatively de- 
pleted in macrophages by leaving adherent cells in the culture flasks. 
Hybridomas.  21-60 d after fusion and maintenance of the fused cells in HAT 
medium,  29.5,  23.9,  and  13.6%  of wells  of fusions  K. J.,  K.  D.,  and  S.  R., 
respectively,  contained  proliferating  hybrid  cells  producing,  by  ELISA,  IgG 
and/or IgM  10 times higher than levels found in spent GM4672 culture super- 
natants  (Table  I).  This corresponds  to a  minimum  fusion  frequency of 6.8  X 
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TABLE  I 
Ig-producing Human-Human Hybridomas  from Human PBL and 
GM 4672 Lymphoblastoid Cells 
Wells positive  Fusion frequency  IgG  IgM  IgG/IgM  Donor  Wells plated  for Ig 
K.J.  200  59 (29.5%)  6.8 ×  10  -5  21  31  7 
K.D.  264  63 (23.9%)  8.4 ×  10  -~  34  25  4 
S.R.  154  21  (13.6%)  1.5 ×  10  -6  11  8  2 
TABLE  II 
Human-Human Hybridoma IgG and~or IgM Reacting with Pf  Antigens and 
Inhibiting In Vitro Parasite Growth 
Wells posi-  FA* reac-  IgG  IgM  lgG/IgM 
Donor 
tive for Ig  tion  Number  GI*  Number  GI ;t  Number  GI* 
K.J.  59  9  5  3  4  l  --  -- 
K.D.  63  5  3  1  1  1  1  1 
S.R.  21  1  --  --  1  1  --  -- 
*  FA, fluorescent antibody reaction. 
GI, in vitro growth inhibition (p <  0.05 relative to control using FA negative hybridoma supernatant 
fluids). 
similar frequency, with a  smaller number of wells containing hybridomas pro- 
ducing both IgG and IgM (Table I). 
Hybridomas  Producing Antiplasmodial  Antibodies.  Of the  143  Ig-yielding hy- 
bridomas, 16 produced IgG/IgM against plasmodial antigens (Table II), accord- 
ing to immune fluorescence. Positive reactions consisted of diffuse fluorescence 
of trophozoites and schizonts typical for immune sera (Fig.  1 A) or fluorescence 
concentrated at the periphery of trophozoites, mature schizonts, and merozoites 
(Fig.  1 B). 
Four  of seven  hybridomas  that  produced  Ig exhibiting  significant  in  vitro 
inhibition of parasite growth could be cloned at a density of 0.3 cells/microtiter 
well  (Table  III).  Preseeding  of wells with  a  feeder  layer  of peripheral  blood 
mononuclear cells did not increase the cloning efficiency. 
Human mAb.  Two consecutive affinity adsorptions on Sepharose 4 B-immo- 
bilized  goat anti-human  IgG allowed  the purification  of human  Ig from cell 
supernatants with good yields. The [35S]methionine-labeled human antibodies of 
the cloned hybridomas, KJ7-2CllD,  KD3-7D3F,  KD5-7A8E,  and KD8-2B2D, 
showed only one heavy and light chain each, by IEF/SDS-PAGE, indicating their 
monocionality. All antibodies  inhibited  the growth of Pf in  vitro  (Table  III), 
reacted strongly with trophozoite/schizont/merozoite surfaces by immune fluo- 
rescence (Fig.  1, A  and B),  and produced,  except for  KJ7-2C11D,  heavy and 
light chains different from those of the GM4672 parent line (Table III). 
Inhibition  of Pf Growth  In  Vitro  by Human  mAb.  Inhibition  of growth  was 
assessed by [35S]methionine metabolically incorporated by synchronized Pf cul- 
tures over a period of 36 h during schizont maturation and merozoite reinvasion; 
only inhibition of 45% or more was significant, applying the double-blind t test. SCHMIDT-ULLRICH ET  AL.  183 
FmURE  1.  mAb from human-human hybridomas,  Fluorescent  antibody reaction with cul- 
tured Pf parasites.  Acetone-fixed  cells were reacted with primary human antibody and then 
with goat anti-human IgG or IgM. A, K. D. (Gambian adult) serum (1:20 dilution). B, mAb 
KJ7-2C11D from culture supernatant. 
TABLE  Ill 
Pf-reactive Human Monoclonal Ig and Their Isotypes 





gglml  % 
KJ3-1B3G  #/K  3.5  -- 
KJ7-2C 11D  7~/K  0.5  90 
KD3-7D3F  #/X  1.2  45 
KD5-7A8E  ~,~/X  4.7  92 
KD5-8C 10B  ~,~/X  15.2  -- 
KD8-2B2D  7~/K  2.3  95 
SR3-1D4B  71/X  0.9 
'y~/K  0.02 
* Based on ELISA; cell density of 106 cells/ml. 
* At Ig concentration of 1 t~g/ml. Tested using the Gambian  K1 strain. 
§ GM4672 is the human lymphoblastoid  cell line used as fusion partner. 
Although  growth  inhibition  of human  mAb  was  normalized  to  1  ~g  Ig  per 
rnil|iliter  of medium (Table  III), one mAb, KJ7-2C11D (IgG2) gave 70% growth 
inhibition  at a  concentration of <50  ng/ml. 
Antigens Recognized by Inhibitory mAb.  Probably due  to selection  by the  inhi- 
bition  assay,  three  of  four  inhibiting  mAb  precipitated  the  Pf  Mr  195,000 
component.  Two  antibodies  also  deposited  Mr  195,000  protein  degradation 
products with Mr near  110,000 and 80,000; and one mAb gave only a very weak 
reaction  with tbe Mr 80,000  protein  (Fig.  2,  lane 4). 184  HUMAN  MONOCLONAL  ANTIBODIES  AGAINST PLASMODIUM  ANTIGEN 
FIGURE 2.  Immune  precipitation  of [35Slmethionine-labeled  Pf antigens  by  human  mAb. 
SDS-PAGE analysis  followed by  [35S]methionine  autoradiography.  As  source  for  mAb,  we 
used affinity-purified Ig from culture supernatants.  In all experiments, 5 x  10  ~ cpm of [ssS  l- 
methionine-labeled antigen were reacted with 0.03 ml of human mAb at a concentration of 5 
#g/ml.  Lane  1, KD5-7A8E; lane 2,  KD3-7D3F; lane 3,  KJ7-2C11D; lane 4,  KDS-2B2D, M~ 
80,000 component (labeled with an arrow); lane 5, human control serum (no malaria exposure); 
lane 6, [~SS]methionine-labeled Pfantigen. 
Discussion 
Our  results  show  that  one  can  produce  human  mAb  to  Pf antigens  using 
hybridomas from human LCL and PBL of individuals immune to Pf malaria, 
and  obtain  a  high  yield  of  Ig-producing  hybridomas  relative  to  previously 
reported (21) experiences with the GM4672  line. The high frequency of IgG- 
secreting hybrid cells may be due to (a) stimulation of the PBL for 6-7  d, at 
which time predominantly IgG-producing lymphocytes elicit a proliferative re- 
sponse (29), and (b) increased susceptibility to mitogen stimulation and/or fusion 
with human LCL of PBL from individuals chronically exposed to malaria and 
other infections. 
Since the experiments in man testing the protective capacity of immune lgG 
from individuals immune to Pf malaria (30), much research has been devoted to 
the humoral immune response to the malarial parasite and the identification of 
potentially protective Plasmodium  blood  stage antigens.  Although polyspecific 
immune sera have allowed the identification of certain candidate antigens (13, 
16,  31),  no  unambiguous  correlation between protection and  antibodies  to a 
defined antigen has been found to date (13,  14). 
The complexity of the immune response to Plasmodium antigens may be due 
to the fact that a given antigen may contain epitopes of very different immuno- 
genicity. Evidence for this is available from gene cloning and DNA-sequencing 
experiments  that  provided  the  amino  acid  sequences  of certain  Plasmodium 
proteins.  These proteins contain repetitive amino acid sequences (32,  33) that SCHM|DT-ULLR1CH  ET  AL.  185 
are highly immunogenic, but antibodies against them do not necessarily provide 
antiplasmodial activity (34, 35). In fact, the function of these peptides may be to 
divert the hosts'  immune response.  At least one category of antigens bearing 
repetitive amino acid sequences, the circumsporozoite (CS) antigen, contains, in 
addition  to  the  tandem  repeat  amino acid  sequences (36),  portions  that  are 
conserved throughout different Plasmodium species (37,  38). Similar conserved 
interspecies peptides  were found for the  Pk Mr 230,000  and  Pf Mr  195,000 
protein (Schmidt-Uilrich and Monroe, unpublished results). 
It  is  reasonable  to  assume  that  similar  proteins  fulfill  similar  functions  in 
different Plasmodiura species,  and  that  conserved  sequences  carry out  these 
functions.  Since  there  is  evidence that  binding  of antibody to  these  moieties 
correlates with damage to the parasite, mAb that truly reflect the immune status 
of the host should be valuable reagents to identify functionally relevant epitopes 
of protective antigens. For Pf malaria, this can currently only be achieved with 
human  mAb.  An  attractive  Pf test  antigen  is  the Mr  195,000  protein.  This 
component has been shown to be a protective antigen in Saimiri monkeys, and 
to be the target antigen for antibodies that inhibit Pf growth in vitro (13,  16). 
The differences of in  vitro  growth inhibition  by Mr  195,000  antigen-reactive 
mAb, produced in our laboratory, support the concept that recognition of certain 
epitopes on  this antigen is essential  for the antibody's biological activity. The 
very effective in vitro growth inhibition of Pf by our human mAb (see also  16) 
relative to some murine mAb against the analogous M~ 230,000  protein of Pk 
(15) suggests that short term immunization with incompatible Plasmodiura para- 
sites does not necessarily lead to the production of antibodies with similar epitope 
specificities as of those antibodies produced by the natural host after exposure 
to malaria over a long time. 
The biological activity of our human mAb and of IgG to the Pf Mr 195,000 
protein  in  one  other  study  (16),  together  with  the  demonstration  that  this 
category of proteins is protective in three host-parasite systems (7, 10,  17) makes 
the Mr  195,000  component a  potential candidate antigen for use as a  vaccine 
against Pf malaria.  One can expect that human mAb against this protein will 
become valuable in  three respects: (a) the identification, characterization, and 
isolation of antigenic peptides of high-Mr schizont/merozoite antigens of human 
Plasmodium, (b)  identification  of portions  of the  Pf genome  encoding these 
peptides,  and  (c)  their  use  as  therapeutic reagents  for  severe cases  of drug- 
resistant malaria. 
Summary 
Using the human lymphoblastoid cell line, GM  4672,  and PBL of Gambian 
adults immune to Plasmodiumfalciparum (PI) malaria, we have produced human- 
human hybridomas and selected those that produce mAb against Pf antigens. 
The fusion frequency, using PWM-stimulated donor lymphocytes was between 
6.8  ×  10 -5 and 1.5 ×  10 -6.  Using immune fluorescence, immune precipitation, 
and Pf in vitro growth inhibition, we cloned four hybridomas that reacted with 
the  Pf Mr  195,000  schizont/merozoite  protein.  The  differences in  proteins 
immune precipitated and in growth inhibition indicate that, during development 
of protective immunity against Pf malaria, a spectrum of antibodies is produced 186  HUMAN  MONOCLONAL ANTIBODIES AGAINST PLASMODIUM ANTIGEN 
reacting  with  different  epitopes  on  the  same antigen.  Only  a  portion  of these 
antibodies exhibits biological activity, suggesting that the recognition of certain 
epitopes is required for the development of a protective immune response. 
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